Concert Pharmaceuticals (NASDAQ:CNCE) issued its earnings results on Thursday. The biotechnology company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.13, Fidelity Earnings reports. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.35 million. Concert Pharmaceuticals had a negative net margin of 7,303.34% and a negative return on equity of 49.44%.
Shares of CNCE stock traded up $0.33 during mid-day trading on Friday, reaching $6.73. The stock had a trading volume of 303,600 shares, compared to its average volume of 223,753. Concert Pharmaceuticals has a 52-week low of $5.36 and a 52-week high of $17.83. The company has a current ratio of 19.63, a quick ratio of 19.63 and a debt-to-equity ratio of 0.12. The stock’s 50-day moving average price is $6.77 and its two-hundred day moving average price is $9.76. The firm has a market capitalization of $152.32 million, a PE ratio of -2.80 and a beta of 0.88.
A number of brokerages recently commented on CNCE. Stifel Nicolaus cut shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their target price for the stock from $18.00 to $8.00 in a research report on Friday, September 27th. SunTrust Banks decreased their target price on shares of Concert Pharmaceuticals from $30.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, September 30th. Janney Montgomery Scott reiterated a “buy” rating and issued a $10.00 target price (down previously from $13.00) on shares of Concert Pharmaceuticals in a research report on Monday, September 30th. Mizuho reiterated a “buy” rating and issued a $18.00 target price on shares of Concert Pharmaceuticals in a research report on Friday. Finally, ValuEngine cut shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $15.63.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
See Also: Put Option
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.